Figure 2 from DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer

Le résumé fourni par la source

Best percentage change in target lesions from baseline for (A) T-DXd + capecitabine and (B) T-DXd + capivasertib. 1L, first-line; 2L, second-line; AKT1, AKT serine/threonine protein kinase 1; BID, twice daily; ctDNA, circulating tumor DNA; HR, hormone receptor; IV, intravenously; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; PO, orally; PTEN, phosphatase and tensin homolog; Q1W, every week; Q3W, every 3 weeks; RECIST 1.1, Response Evaluation Criteria in Solid Tumors version 1.1; T-DXd, trastuzumab deruxtecan. T-DXd + capecitabine, n = 20. T-DXd + capivasertib, n = 40; patients with PIK3CA/AKT1/PTEN-altered tumors, n = 13; patients with PIK3CA/AKT1/PTEN-non-altered tumors, n = 21; and patients with an unknown/ctDNA low status, n = 6. aT-DXd 5.4 mg/kg IV Q3W + capecitabine 750 mg/m2 PO BID on Days 1–14 Q3W. bTwo patients (10.0%) did not have any post-baseline RECIST 1.1 data and thus no data were available for best percentage change in target lesion size. cT-DXd 5.4 mg/kg IV Q3W + capivasertib 400 mg PO BID Q1W on Days 1–4 within a 21-day cycle. ∗1L treatment setting. †2L treatment setting.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.